Just posted on Linkedin6 Aug 2025 17:43
Https://www.linkedin.com/company/scancell-limited/posts/?feedView=all
Last month Scancell published data from the translational, open-label study Phase II SCOPE study of SCIB1/iSCIB1+ in advanced unresectable stage III/IV melanoma.
Immunobody® DNA active immunotherapies iSCIB1/iSCIB1+ plus standard of care successfully achieved the SCOPE study objectives, showing excellent results encompassing efficacy, durability, immune responses and safety. The key aims were to select the optimal candidate for future development and to define the target patient population.
SCIB1 efficacy is restricted to 30% to 40% of patients with the appropriate HLA haplotype, whereas iSCIB1+ addresses a much wider HLA patient population. The latest SCOPE data have clarified that iSCIB1+ works as expected in the predicted HLA types, which represent 80% of melanoma patients - effectively double that of SCIB1.
SCOPE data for iSCIB1+ in the target HLA patients appear to show around a 20% improvement in several parameters, including overall response rate and progression free survival, when benchmarked against historical standard of care data. This has accelerated development plans for a potentially pivotal Phase IIb/III trial, with Scancell planning to meet with the FDA later this year.
🖥️ View the presentation: https://lnkd.in/dAadxmwQ